Our latest articles
Asco 2023 – Enhertu hits with pan approach
Strong data prompt talk of a tumour-agnostic approval, but regulators could prove reluctant in the broad Her2 setting.
Asco 2023 – Bicara eyes head and neck niche
Impressive data in HPV-negative disease, potentially beating Keytruda, has the private group making pivotal plans.
Asco 2023 – liver tox casts a pall over Servier’s Indigo readout
Vorasidenib, potentially the first targeted therapy for low-grade glioma, comes at a toxicity price.
Asco 2023 – Roche sees Morpheus and takes the red pill
The company’s Tigit data are strong enough for a phase 3 trial to be launched, Asco learns.
Asco 2023 – Trop2 could validate Merck’s savvy deal with Kelun
In Trop2 Merck & Co might have got itself an ADC at least as good as Gilead and Astra/Daiichi’s leaders, for a fraction of the price.
Asco 2023 – deep and early responses lift hopes at Effector
New data with a novel RNA translation regulator gave the stock a pre-Asco boost, but the micro-cap company needs to keep the momentum going.
Asco 2023 – Pfizer pushes forward in drug-resistant breast cancer
While Ibrance has been bested by class rivals, Pfizer is working on projects that might overcome CDK4/6 inhibitor resistance – though it is not alone.
Asco 2023 – Elevation follows in Astellas’s slipstream
There is reason for the enthusiasm behind Elevation’s anti-Claudin18.2 ADC, but no such good news for Zai Lab’s zolbetuximab challenger.
Asco 2023 – a role for immuno-oncology in ovarian cancer at last?
Astra’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.
Asco 2023 – Novartis’s adjuvant breast cancer win comes with caveats
The Natalee trial hits in all-comers, but an equivocal showing in node-negative patients raises questions about market expansion.